ACTHREL SUMMARY
ACTHREL®
(corticorelin ovine triflutate for injection)
For intravenous injection only
DIAGNOSTIC USE ONLY
ACTHREL® (corticorelin ovine triflutate for injection) is a sterile, nonpyrogenic, lyophilized white cake powder, containing corticorelin ovine triflutate, a trifluoroacetate salt of a synthetic peptide that is used for the determination of pituitary corticotroph responsiveness. Corticorelin ovine has an amino acid sequence identical to ovine corticotropin-releasing hormone (oCRH). Corticorelin ovine is an analogue of the naturally occurring human CRH (hCRH) peptide. Both peptides are potent stimulators of adrenocorticotropic hormone (ACTH) release from the anterior pituitary. ACTH stimulates cortisol production from the adrenal cortex.
ACTHREL® is indicated for use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.
|
NEWS HIGHLIGHTSMedia Articles Related to Acthrel (Corticorelin Ovine Triflutate)
Potential Therapeutic Target Discovered For Cushing's Disease
Source: Endocrinology News From Medical News Today [2013.05.10]
Scientists at the Salk Institute for Biological Studies have identified a protein that drives the formation of pituitary tumors in Cushing's disease, a development that may give clinicians a therapeutic target to treat this potentially life-threatening disorder...
Clinical Trials Related to Acthrel (Corticorelin Ovine Triflutate)
Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency [Completed]
Corticotropin Releasing Hormone (CRH) is a hypothalamic hormone made up of 41 amino acids.
Amino acids are proteins that when combined make up different substances, like hormones. The
order of amino acids in CRH, has been determined, meaning that the hormone can now be
synthetically reproduced in a laboratory setting.
When CRH is released from the hypothalamus it stimulates the pituitary gland to secrete
another hormone, ACTH. ACTH then causes the adrenal glands to make a third hormone,
cortisol. This process is known as the hypothalamic-pituitary-adrenal axis. Problems can
occur in any of the steps of this process and result in a variety of diseases (Cushing's
Syndrome and adrenal insufficiency).
Researchers hope that CRH created in a laboratory setting, ovine CRH (oCRH) can be used to
help diagnose and treat conditions of the HPA axis. This study will test the relationship
for single doses of oCRH in normal volunteers and patients with disorders of the HPA axis.
The oCRH will be injected into the patients vein as a single injection or slowly through an
IV line over 24 hours. The participants will have blood tests taken to measure hormone
levels before, during, and after receiving the oCRH.
XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema [Withdrawn]
The purpose of this study is to examine the safety and efficacy of XERECEPT (human
Corticotropin-Releasing Factor, or hCRF) compared to dexamethasone in patients with primary
malignant glioma who require increased dexamethasone doses to control symptom of peritumoral
brain edema.
An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies [Recruiting]
The purpose of this study is to examine the long-term safety and tolerability of human
corticotropin-releasing factor (hCRF), XERECEPT®, in patients requiring dexamethasone
(Decadron) to treat peritumoral brain edema. This open-label, extended-use study is open to
all patients who participate in either of the blinded studies, NTI 0302, NTI 0303, or other
designated studies, including patients who may have discontinued blinded study medication
early but completed the protocol-stipulated follow-up periods.
Tolerability Study of Xerecept� in Pediatric Patients [Recruiting]
This study is being conducted to evaluate the safety and tolerability of Xerecept® in
children with central nervous system tumors and to identify appropriate doses of Xerecept®
to be used in subsequent pediatric clinical trials.
Effects of Corticotropin Releasing Hormone (CRH) on the Sleep in Patients With Hypopituitarism [Recruiting]
In contrast to healthy subjects, patients with hypopituitarism do not exhibit endocrine
responses when hormones are injected. This is at least true for those with a complete
insufficiency of the anterior pituitary. For example, administration of corticotropin
releasing hormone (CRH) is not followed by an increase of ACTH and cortisol. Therefore,
"pure" hormone effects can be investigated.
It is well established that hormones of the hypothalamic-pituitary-adrenal axis are involved
in sleep regulation. In rodents, CRH decreased slow wave sleep (SWS). In humans, CRH was
reported to increase wakefulness and to decrease SWS and REM sleep. Primary objective was
therefore to study the effect of CRH on patients with hypopituitarism.
To date, there is no information on sleep of patients with hypopituitarism. Secondary
objective is therefore to compare sleep of patients with hypopituitarism with sleep of
age-matched healthy controls.
|
